Literature DB >> 30660783

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.

James R Klinger1, C Gregory Elliott2, Deborah J Levine3, Eduardo Bossone4, Laura Duvall5, Karen Fagan6, Julie Frantsve-Hawley7, Steven M Kawut8, John J Ryan9, Erika B Rosenzweig10, Nneka Sederstrom11, Virginia D Steen12, David B Badesch13.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) carries a poor prognosis if not promptly diagnosed and appropriately treated. The development and approval of 14 medications over the last several decades have led to a rapidly evolving approach to therapy, and have necessitated periodic updating of evidence-based treatment guidelines. This guideline statement, which now includes a visual algorithm to enhance its clinical utility, represents the fourth iteration of the American College of Chest Physicians Guideline and Expert Panel Report on Pharmacotherapy for PAH.
METHODS: The guideline panel conducted an updated systematic review to identify studies published after those included in the 2014 guideline. A systematic literature search was conducted using MEDLINE via PubMed and the Cochrane Library. The quality of the body of evidence was assessed for each critical or important outcome of interest using the Grading of Recommendations Assessment, Development and Evaluation approach. Graded recommendations and ungraded consensus-based statements were developed and voted on using a modified Delphi technique to achieve consensus.
RESULTS: Two new recommendations on combination therapy and two ungraded consensus-based statements on palliative care were developed. An evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management, and to direct readers to the appropriate area of the document for more detailed information.
CONCLUSIONS: Therapeutic options for the patient with PAH continue to expand through basic discovery, translational science, and clinical trials. Optimal use of new treatment options requires prompt evaluation at an expert center, utilization of current evidence-based guidelines, and collaborative care using sound clinical judgment.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  evidence-based medicine; guidelines; pulmonary arterial hypertension (PAH)

Mesh:

Substances:

Year:  2019        PMID: 30660783     DOI: 10.1016/j.chest.2018.11.030

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  63 in total

1.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.

Authors:  Vivek Nagaraja; Marco Matucci-Cerinic; Daniel E Furst; Masataka Kuwana; Yannick Allanore; Christopher P Denton; Ganesh Raghu; Vallerie Mclaughlin; Panduranga S Rao; James R Seibold; John D Pauling; Michael L Whitfield; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2020-05-18       Impact factor: 10.995

2.  Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.

Authors:  Hongyang Pi; Chad M Kosanovich; Adam Handen; Michael Tao; Jacqueline Visina; Gabrielle Vanspeybroeck; Marc A Simon; Michael G Risbano; Aken Desai; Michael A Mathier; Belinda N Rivera-Lebron; Quyen Nguyen; Jennifer Kliner; Mehdi Nouraie; Stephen Y Chan
Journal:  Chest       Date:  2020-02-25       Impact factor: 9.410

3.  Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.

Authors:  Nathane Santanna Felix; Lucas de Mendonça; Cassia Lisboa Braga; Jaqueline Soares da Silva; Cynthia Dos Santos Samary; Juliana Borges Vieira; Fernanda Cruz; Nazareth de Novaes Rocha; Gisele Zapata-Sudo; Patricia Rieken Macedo Rocco; Pedro Leme Silva
Journal:  Br J Pharmacol       Date:  2019-12-05       Impact factor: 8.739

4.  Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.

Authors:  Chi Yan Wong; Kwok Wai Tsang; Cho Wing Li; Ho Yan Au; Kwok Ying Chan
Journal:  AME Case Rep       Date:  2021-01-25

5.  Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes.

Authors:  Vidhu Anand; Saraschandra Vallabhajosyula; Wisit Cheungpasitporn; Robert P Frantz; Hector R Cajigas; Jacob J Strand; Hilary M DuBrock
Journal:  Chest       Date:  2020-08-12       Impact factor: 9.410

6.  Endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Chao Liu; Junmin Chen; Yanqiu Gao; Bao Deng; Kunshen Liu
Journal:  Cochrane Database Syst Rev       Date:  2021-03-26

Review 7.  Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5.

Authors:  Kathryn J Lindley; C Noel Bairey Merz; Anita W Asgar; Natalie A Bello; Sonal Chandra; Melinda B Davis; Mardi Gomberg-Maitland; Martha Gulati; Lisa M Hollier; Eric V Krieger; Ki Park; Candice Silversides; Natasha K Wolfe; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2021-04-13       Impact factor: 24.094

8.  Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension.

Authors:  Sankar D Navaneethan; Carl P Walther; L Parker Gregg; Shweta Bansal; Wolfgang C Winkelmayer; Vijay Nambi; Jingbo Niu
Journal:  Am J Kidney Dis       Date:  2021-04-24       Impact factor: 8.860

9.  A 44-Year-Old Man Presenting With Massive Hemoptysis and Dyspnea.

Authors:  Laura J Oppegard; Grady Hedstrom; Jacqueline Levene; Sima Desai; Akram Khan; Jessica L Tsui
Journal:  Chest       Date:  2021-04-06       Impact factor: 9.410

10.  United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics.

Authors:  Jessica B Badlam; David B Badesch; Eric D Austin; Raymond L Benza; Wendy K Chung; Harrison W Farber; Kathy Feldkircher; Adaani E Frost; Abby D Poms; Katie A Lutz; Michael W Pauciulo; Chang Yu; William C Nichols; C Gregory Elliott
Journal:  Chest       Date:  2020-08-26       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.